Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-EXOSC10 Antibody (R3Q41)

Catalog #:   RHF89101 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG2a
Applications: IP, WB
Accession: Q01780
Overview

Catalog No.

RHF89101

Species reactivity

Human

Host species

Mouse

Isotype

IgG2a

Clonality

Monoclonal

Tested applications

IP: 1:100-1:200, WB: 1:500-1:1000

Target

PMSCL2, EXOSC10, Exosome component 10, P100 polymyositis-scleroderma overlap syndrome-associated autoantigen, PM/Scl-100, Autoantigen PM/Scl 2, PMSCL, Polymyositis/scleroderma autoantigen 100 kDa, Polymyositis/scleroderma autoantigen 2, RRP6

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q01780

Applications

IP, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R3Q41

Data Image
  • Immunoprecipitation
    Lane 1: HEK-293 lysate ; Lane 2: EXOSC10 immunoprecipitated from HEK-293 lysate by RHF89101;Lane 3: The same as Lane 2 but use IgG isotype control antibody ;Result: RHF89101 can immunoprecipitate EXOSC10;
  • Western blot
    Western blot analysis using EXOSC10 mouse mAb against HEK-293 lysate
References

Patients with anti-PM/Scl-positive and idiopathic inflammatory myopathy resemble anti-synthetase syndrome., PMID:39953567

Clinical characteristics of idiopathic inflammatory myopathies patients with anti-PM/Scl antibodies., PMID:39178740

RNA exosome drives early B cell development via noncoding RNA processing mechanisms., PMID:35658015

The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort., PMID:33580257

Autoantibodies in outbred Swiss Webster mice following exposure to gold and mercury., PMID:33358697

The Relationship Between Autonomic Dysfunction of the Gastrointestinal Tract and Emotional Distress in Patients With Systemic Sclerosis., PMID:31524844

High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids., PMID:31428516

Performance evaluation of a line blot assay system for detection of anti-PM-Scl antibody in Japanese patients with systemic sclerosis., PMID:31245910

Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis., PMID:30047434

Anti-PM/Scl antibody-positive dermatomyositis in a Japanese patient: a case report and review of the literature., PMID:28185425

Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options., PMID:27908312

Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis., PMID:26246178

RNA exosome-regulated long non-coding RNA transcription controls super-enhancer activity., PMID:25957685

Anti-SSA/Ro52 autoantibodies in scleroderma: results of an observational, cross-sectional study., PMID:25372801

Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients., PMID:24577935

Myopathy in scleroderma, its identification, prevalence, and treatment: lessons learned from cohort studies., PMID:24419752

Skin lesions in anti-Pm-Scl-70 positive systemic sclerosis-dermatomyositis overlap syndrome improve during local PUVA phototherapy., PMID:24126033

[Systemic sclerosis autoantibodies: what dermatologists must know]., PMID:23395500

Fluoroenzymeimmunoassay to detect systemic sclerosis-associated antibodies: diagnostic performance and correlation with conventional techniques., PMID:22765957

Evaluation of a new multi-parallel line immunoassay for systemic sclerosis-associated antibodies in an Asian population., PMID:22491717

Anti-PM-Scl antibody in patients with systemic sclerosis., PMID:22261302

Diagnostic assays for anti-PM/Scl IgG antibodies: heterogeneity in antibody response or lack of standardization?, PMID:21371448

[Anti-polymyositis-scleroderma(PM-Scl) antibody]., PMID:20942126

[How can we diagnose and better understand inflammatory myopathies? The usefulness of auto-antibodies]., PMID:20655695

[Idiopathic inflammatory myopathies with anti-PM-Scl antibodies: case series and literature review]., PMID:20510485

Anti-PM/Scl-100 and anti-RNA-polymerase III antibodies in scleroderma., PMID:20346932

Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?, PMID:20231208

Antibodies to fibrillarin, PM-Scl and RNA polymerase III detected by ELISA assays in patients with systemic sclerosis., PMID:20138166

The human exosome and disease., PMID:21618880

Long-term outcome of patients with polymyositis/ dermatomyositis and anti-PM-Scl antibody., PMID:19845665

HLA-DPB1 associations differ between DRB1*03 positive anti-Jo-1 and anti-PM-Scl antibody positive idiopathic inflammatory myopathy., PMID:19690132

The changing landscape of the clinical value of the PM/Scl autoantibody system., PMID:19351430

Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients., PMID:19220911

PM1-Alpha ELISA: the assay of choice for the detection of anti-PM/Scl autoantibodies?, PMID:19103309

Clinical significance of elevated antinuclear antibody test in patients with Hodgkin's and Non-Hodgkin's lymphoma: a single center experience., PMID:18299692

Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy., PMID:17013837

[Anti PM-Scl antibodies. Study of prevalence and of meaning]., PMID:16797795

Dysphagia associated with anti-PM-Scl antibodies in systemic lupus erythematosus., PMID:16641054

Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease., PMID:16583463

[PM-Scl antibody positive systemic sclerosis associated with inclusion-body myositis]., PMID:16244833

[Immunologic tests: Anti-polymyositis-scleroderma (PM-Scl) antibody]., PMID:16111314

Patients with antibodies to both PmScl and dsDNA., PMID:15517629

PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome., PMID:14872500

Anti-PM-Scl antibodies in a patient with inclusion body myositis., PMID:12869677

Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients., PMID:12136894

Case 26-2001: scleroderma renal crisis and polymyositis., PMID:12063382

Autoantibodies directed to novel components of the PM/Scl complex, the human exosome., PMID:11879549

Acquired haemophilia and PM-Scl antibodies., PMID:10952757

Identification of an alpha-helical epitope region on the PM/Scl-100 autoantigen with structural homology to a region on the heterochromatin p25beta autoantigen using immobilized overlapping synthetic peptides., PMID:10759029

[Anti-PM-Scl antibody]., PMID:10635874

Datasheet
$ 220
Product specifications
50 μg 220 100 μg 350

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-EXOSC10 Antibody (R3Q41) [RHF89101]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only